ERIVEDGE — Competitive Intelligence Brief

ERIVEDGE (ERIVEDGE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hedgehog pathway inhibitor. Area: Oncology.

marketed Hedgehog pathway inhibitor Smoothened (SMO) Oncology Small molecule

Target snapshot

ERIVEDGE (ERIVEDGE) — University Hospital, Lille. Erivedge (vismodegib) inhibits the Hedgehog signaling pathway by blocking Smoothened, a key transmembrane protein required for pathway activation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ERIVEDGE TARGET	ERIVEDGE	University Hospital, Lille	marketed	Hedgehog pathway inhibitor	Smoothened (SMO)
Daurismo	Glasdegib Maleate	Pfizer	marketed	Hedgehog pathway inhibitor	Smoothened (transmembrane protein)	2018-01-01
GLASDEGIB	GLASDEGIB		marketed	Hedgehog Pathway Inhibitor [EPC]		2018-01-01
Daurismo	glasdegib	Pfizer	marketed	Hedgehog Pathway Inhibitor [EPC]	Smoothened homolog	2018-01-01
Erivedge	vismodegib	Roche	marketed	Hedgehog Pathway Inhibitor [EPC]	Smoothened	2012-01-01
Sonidegib Phosphate Capsules	Sonidegib Phosphate Capsules	Jemincare	marketed	Hedgehog pathway inhibitor	Smoothened (SMO)
Treatment with vismodegib	Treatment with vismodegib	University Hospital, Bordeaux	marketed	Hedgehog pathway inhibitor	Smoothened (SMO)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hedgehog pathway inhibitor class)

1. Jemincare · 1 drug in this class
2. Pfizer · 1 drug in this class
3. University Hospital, Bordeaux · 1 drug in this class
4. University Hospital, Lille · 1 drug in this class